Genitourinary Cancers

To guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.

A novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.

In a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.

Also look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.

Peter C. Black, MD, discusses the current state of immune checkpoint inhibition for bladder cancer in this article from Urology Times SUO internship program member William Parker, MD.

Urology Times SUO internship program member Robert M. Turner, II, MD, reports on a recent presentation by J. Stuart Wolf, Jr., MD, about possible pitfalls of renal mass biopsy.

Nurse practitioner Adele M. Caruso, MSN, CRNP, discusses appropriate timing of follow-up and ponders related health insurance coverage and cancer survivorship issues.

Urology Times SUO internship program member Katie Murray, DO, reports on a study evaluating the differences in urine cytology and UroVysion FISH testing results among clinically meaningful patient subgroups.

Urology Times SUO internship program member William Parker, MD, discusses a retrospective review of more than 100 patients at Columbia University Medical Center in New York.

Urology Times SUO internship program member Brandon Manley, MD, reports on an SUO presentation highlighting several interesting findings on advanced prostate cancer with variant histology.

Check out the latest new products. From Single-use ureteroscope addresses shortcomings of reusable scopes, to an App that helps IC, chronic prostatitis patients choose the right foods and much more.

In this interview, E. Jason Abel, MD, discusses biopsy’s role in small and large renal masses, associated risks, and when patients can be safely observed.

Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.

Learn more about these products as well as a powered exam table and an app that measures, monitors, and helps improve fertility in men.

In this interview Mark A. Preston, MD, MPH, of Brigham and Women’s hospital sat down with Richard. R. Kerr, Urology Times content channel director, to discuss the association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts. The interview was conducted during the AUA annual meeting in New Orleans.

Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.

Other products highlighted in this slideshow include a trial system for incontinence therapy, a compact catheter, a wearable digital technology solution for continence care assessment and management, and laser fiber and sheath system.

A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.

Work-related risks for bladder cancer are on the rise, but the occupations putting workers at risk seem to be evolving, according to a meta-analysis published online in JAMA Oncology (Oct. 8, 2015).

Study findings point to “a concept that has haunted clinical trialists for years,” says one expert.

An immune checkpoint inhibitor provides “a real opportunity to change clinical practice” for patients with metastatic renal cell carcinoma, a study author says.

Researchers have recently made progress in understanding a fundamental signaling cascade, the Programmed Death 1 (PD-1) receptor-ligand pathway,1 which holds long-awaited promise in bladder cancer intervention.

In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.

A new study reports no statistically significant increase in the risk of bladder cancer among patients treated with the diabetes drug pioglitazone (Actos), despite previous studies suggesting an association.

In this round-up of new urology products and services, learn about an app that helps moviegoers with OAB, a new mesh for sacrocolpopexy, and device/smartphone app that help women with pelvic floor exercises.